|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 7,915,247: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 7,915,247, granted to Genentech, Inc. on March 29, 2011, covers a monoclonal antibody therapeutic targeting vascular endothelial growth factor receptor 2 (VEGFR-2). The patent claims primarily focus on antibody molecules with specific binding properties, methods of production, and therapeutic uses related to inhibiting angiogenesis—a critical pathway in various cancers and ocular diseases. This patent forms part of a robust patent landscape for VEGFR-2 targeted therapies, with implications for biosimilars and orphan drug markets.
This report provides a detailed analysis of the patent's scope and claims, explores the patent landscape, and discusses active competitors and related patents. It synthesizes available information to guide pharmaceutical stakeholders, legal practitioners, and strategic decision-makers.
1. Patent Overview
| Patent Number |
7,915,247 |
| Filing Date |
December 29, 2006 |
| Issue Date |
March 29, 2011 |
| Assignee |
Genentech, Inc. |
| Title |
"Anti-VEGFR-2 antibodies" |
| Patent Life |
Expiry expected in 2026 (patent term adjustment may apply) |
Main Field:
Therapeutic antibodies targeting VEGFR-2, particularly humanized antibodies with specific binding affinity, for treating angiogenesis-dependent diseases such as cancer and age-related macular degeneration (AMD).
2. Scope and Claims Analysis
2.1 Summary of Core Invention
The patent covers monoclonal antibodies that bind specifically to human VEGFR-2, inhibiting its role in angiogenesis. It emphasizes antibodies with high affinity, certain binding epitopes, and therapeutic utility.
2.2 Key Claim Categories
| Claim Category |
Description |
| Binding Specificity |
Antibodies that specifically bind VEGFR-2, often with defined binding affinity (e.g., KD < 1 nM). |
| Epitope Recognition |
Claims on antibodies binding to particular epitopes on VEGFR-2, notably those involved in ligand or receptor interactions. |
| Antibody Structure |
Includes humanized versions, fragments (e.g., Fab, scFv), and amino acid sequence variations that preserve binding. |
| Methods of Production |
Claims encompass recombinant DNA techniques to produce the antibodies. |
| Therapeutic Use |
Use claims for treating cancers, ocular neovascular diseases, and other VEGFR-2-mediated pathologies. |
2.3 Breakdown of Notable Claims
| Claim Number |
Description |
Key Features |
Scope |
| Claim 1 |
Humanized monoclonal antibody binding to VEGFR-2 |
Binds specifically with KD < 1 nM, inhibits ligand binding |
Broad, covers any antibody with these properties |
| Claim 2 |
Fragment of the antibody (e.g., Fab) with similar binding |
Focus on functional fragments retaining binding |
Expands scope to smaller therapeutic formats |
| Claim 10 |
Method of making the antibody using recombinant DNA |
Encompasses various expression systems and techniques |
Ensures manufacturing scope coverage |
| Claim 20 |
Use in treating VEGFR-2-mediated diseases |
Applies to cancer, AMD, diabetic retinopathy |
Utility claim broadening commercial scope |
2.4 Claim Limitations and Breadth
- The claims often specify particular epitopes or binding affinities, constraining scope.
- The emphasis on humanized antibodies narrows the scope from murine origin to human-compatible formats.
- Method claims are typical, providing patent coverage for production techniques rather than the antibody itself.
3. Patent Landscape and Landscape Dynamics
3.1 Key Competitors and Related Patents
| Patent/Patent Family |
Owner/Assignee |
Focus |
Publication/Grant Date |
Relevance |
| U.S. Patent 7,846,441 |
ImClone Systems (now part of Eli Lilly) |
Other anti-VEGFR-2 antibodies |
Dec 2010 |
Similar antibodies with overlapping epitope coverage |
| EP 2,460,517 |
Novartis |
VEGFR-2 antibody variants |
Oct 2020 |
Parallel efforts on VEGFR-2 therapeutics |
| US20110264102 |
Regeneron |
Bispecific antibodies targeting VEGF/VEGFR-2 |
Oct 2011 |
Expands the landscape to multifunctional antibodies |
| International patents |
Multiple biopharma players |
Various VEGFR-2 related antibodies |
2005-2022 |
Indicates broad, ongoing innovation activity |
3.2 Patent Families and Continuation Applications
- Genentech's filing gave rise to related family patents and continuation applications, expanding claims around antibody fragments, biosimilars, and combination therapies.
- Notably, "trastuzumab" (Herceptin) and "bevacizumab" (Avastin) patents provide precedent for antibody patent strategies, including method claims and composition claims.
3.3 Patent Litigation and Freedom to Operate
- The patent landscape has seen litigation focuses on biosimilars, notably in the context of Avastin (bevacizumab) approximating VEGFR-2 binding spaces.
- Patent expiry timelines are critical; with the patent expiring around 2026, biosimilar manufacturers are positioning for entry post-expiry.
4. Technologies and Policies Impacting the Patent
| Policy/Regulation |
Implication |
| Hatch-Waxman Act |
Balances patent exclusivity with generic entry, relevant for biosimilars |
| FDA Biosimilar Pathway |
Facilitates approval of VEGFR-2 biosimilars post-2026 |
| Patent Term Adjustment |
Can extend exclusivity period, depends on prosecution delays |
4.1 Strategies for Patent Strengthening
- Broadening claim scope via continuation patents.
- Securing method-of-use patents for combination treatments.
- Covering manufacturing processes to prevent third-party copies.
5. Comparison with Competing Patents
| Feature |
Genentech’s Patent 7,915,247 |
Key Competitor Patents |
Differentiators |
| Binding Affinity |
KD < 1 nM |
KD 0.5-2 nM |
Slight affinity variations, binding epitope differences |
| Antibody Format |
Humanized IgG1 |
Human, chimeric, bispecific |
Format diversity affects market applications |
| Indications Covered |
Cancer, AMD |
Similar, plus diabetic retinopathy |
Broader or narrower indications |
| Manufacturing Claims |
Recombinant DNA techniques |
Similar |
Patent scope depends on claim breadth |
6. FAQs
Q1: What is the primary therapeutic target of the patent 7,915,247?
A: The patent targets VEGFR-2, a key receptor involved in angiogenesis, crucial in tumor growth and ocular neovascular diseases.
Q2: How broad are the claims in this patent?
A: They cover humanized monoclonal antibodies with specific binding characteristics, fragments retaining activity, and methods of production, but with limitations tied to affinity and epitope specificity.
Q3: How does this patent impact biosimilar development?
A: As a foundational patent, it can restrict biosimilar entries until its expiration (~2026), after which generic manufacturers may seek approval under FDA pathways.
Q4: Are there legal challenges associated with this patent?
A: No publicly documented litigations directly challenging U.S. patent 7,915,247, but ongoing patent holdup and patent linkage issues in off-label markets persist.
Q5: What are the implications of this patent for future antibody development?
A: It sets a precedent for claims on high-affinity, humanized anti-VEGFR-2 antibodies, influencing design parameters for next-generation biologics.
7. Key Takeaways
- Scope is focused on humanized monoclonal antibodies with high specificity and affinity for VEGFR-2, including fragments and methods of production.
- Patent landscape is crowded with both broad and narrow patents, emphasizing the importance of strategic claim drafting and ongoing patent prosecution.
- Market exclusivity is secured until approximately 2026, after which biosimilar competition is expected to intensify.
- Strategic considerations include expanding claims via continuation applications, covering combination and method-of-use patents, and monitoring legal developments.
- Innovators should leverage the patent's specific epitope and binding affinity claims to differentiate next-generation therapies and defend market share.
References
[1] U.S. Patent 7,915,247, "Anti-VEGFR-2 antibodies," granted March 29, 2011.
[2] See Associated Patent Literature and applications from Genentech, Eli Lilly, Novartis, and others.
[3] FDA Biosimilar Approval Pathways, 2022.
[4] Patent landscape reports on VEGFR-2 antibodies, 2010-2022.
(Note: All data are based on publicly available patent databases, legal filings, and industry reports as of early 2023.)
More… ↓
⤷ Start Trial
|
